In this trial, subjects were randomized to receive tofersen or placebo, focusing on changes in ALS Functional Rating Scale-Revised (ALSFRS-R) scores as well as CSF SOD1 and plasma NfL levels. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.